Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-702 plus irinotecan as third-line therapy for MET or EGFR overexpressing gastric cancer
KCT0008025Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CKD-702 in gastric cancer (GC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Dec 2022; status: recruiting.
02
Drugs
CKD-702
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0008025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008025.